EQ – Market Data & News
Shares of Equillium Inc (NASDAQ: EQ) fell 7.04% Monday.
As of 11:36:34 est, Equillium is currently sitting at $2.51 and dropped $0.19 so far today.
Equillium has moved 17.39% over the last 30 days and has moved YTD 28.38% based on the most recent close.
The company is set to release earnings on 2022-08-09.
For technical charts, analysis, and more on Equillium visit the company profile.
About Equillium Inc
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.
To get more information on Equillium Inc and to follow the company's latest updates, you can visit the company's profile page here: Equillium Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.
Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.
Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer
Loading…
End of content
No more articles to load
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Follow Equillium Inc.